Life sciences SPAC JATT Acquisition closed its IPO of 13.8 million units, including 1.8 million units sold to the underwriters in the full exercise of their over-allotment option.
Units trade on the NYSE under JATT U. Each consists of one Class A ordinary share and one-half of one redeemable warrant; whole warrants exercisable at $11.50.
Once the securities comprising the units begin separate trading, shares and warrants are expected to trade under JATT and JATT WS.
Dr. Someit Sidhu is CEO and director of the new SPAC. He is also the co-founder and CEO of Akaza Bioscience and the CEO of Izana Bioscience, as well as the co-founder of Pathios Therapeutics. Read more.
